Skip to main content
. 2017 Jan 17;9(3):506–520. doi: 10.1080/19420862.2016.1274844

Figure 5.

Figure 5.

Expression and purification of human and murine GpL(CT-LC)-IgG variants of 18D1. (A, B) Purified GpL(CT-LC)-18D1-IgG2, GpL(CT-LC)-18D1-mIgG1 and GpL(CT-LC)-18D1-mIgG2a (200 ng) were analyzed by SDS-PAGE (A) and gel filtration (B). (C) Equilibrium binding studies with the various novel GpL(CT-LC)-18D1-IgG variants and HT1080 and HT1080-Fn14-KO cells were performed as in Fig. 2B to determine their affinity for cell expressed Fn14. Shown is one representative experiment for each fusion protein. (D) Determination of the KD values of 18D1-IgG2, 18D1-mIgG1 and 18D1-mIgG2a by competition binding experiments with 100 ng/ml of GpL(CT-LC)-18D1-IgG2, GpL(CT-LC)-18D1-mIgG1 and GpL(CT-LC)-18D1-mIgG2a.